Objective: This systematic review aimed to evaluate the nephroprotective effect of Panax notoginseng.Methods: The search for scientific articles in the literature was carried out in the Medline (PubMed), Web of Science, Embase, and Virtual Health Library (BVS) databases. Eligibility criteria consisted of preclinical in vivo or clinical studies that demonstrated the nephroprotective effect of Panax notoginseng, as assessed by one or more of the following laboratory tests: serum creatinine, serum urea, glomerular filtration rate, creatinine clearance, proteinuria, or albuminuria. Results: Fourteen articles were included, all of which consisted of preclinical trials. The nephropathy models used in the studies were diabetic kidney disease (n=8), kidney injury induced by nephrotoxic substances (n=5), or ischemia (n=1). All studies showed that Panax notoginseng has a nephroprotective effect when used in the treatment of kidney diseases. Although three studies did not observe a reduction in serum creatinine and/or urea levels, these studies found that albuminuria decreased significantly. Conclusion: Panax notoginseng has a nephroprotective effect in different animal models of nephropathy. The clinical use of Panax notoginseng tends to be promising as an adjuvant in the pharmacotherapy of renal dysfunctions and in the prevention of drug-induced nephrotoxicity.
Read full abstract